Hope Northrup
Clinical Genetics (M.D.) · Houston, TXNPI 1740218296
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 93.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $45,480 and has fallen 84.4% since, to $7,101 in 2025. Among clinical genetics (m.d.) clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $644.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$168K
- PTC Therapeutics, Inc.$5K
- Ipsen Innovation$3K
- Modernatx, Inc.$1K
- Novartis$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$914
- plus $1K from 4 others
Across 145 payments — averaging $7533.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$852K
- PTC Therapeutics, Inc.$185K
- Modernatx, Inc.$53K
- Sanofi US Services Inc.$3K
What the payments were for
- Consulting fees$16,6679%
- Speaking & faculty fees$98,68355%
- Travel & lodging$52,07929%
- Food & beverage$6,5164%
- Education$5,7643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 238 | $167,587 |
| PTC Therapeutics, Inc. | 3 | $5,210 |
| Ipsen Innovation | 1 | $2,700 |
| Modernatx, Inc. | 13 | $1,247 |
| Novartis | 10 | $1,024 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $914 |
| Cycle Pharmaceuticals Inc | 3 | $750 |
| Mirum Pharmaceuticals, Inc. | 1 | $142 |
| Ultragenyx Pharmaceutical Inc. | 1 | $117 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Palynziq$133,585
- Kuvan$77,708
- Nityr$600
- VIJOICE$368
- SEPHIENCE$210
- Livmarli$142
- (810) Chenodal$142
- (820) Cholbam$142
- DOJOLVI$117
How this compares
$179,710 in reported general payments places this provider in the 90th percentile of 37 clinical genetics (m.d.) providers in Texas.
Other clinical genetics (m.d.) in Houston
- Paul HillmanHouston$68K
- Brendan LeeHouston$28K
- David RodriguezHouston$28K
- Fernando ScagliaHouston$16K
- Claudia Soler-AlfonsoHouston$4K
- Andres Caceres SalgadoHouston$387
- Lilei ZhangHouston$193
- Laura FarachHouston$173
- Roni Zemet LazarHouston$172
- Lindsay BurrageHouston$23
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.